Oncoclínicas do Brasil Serviços Médicos (ONCO3) Q4 2025 earnings summary

Executive summary

• Leadership transition and strategic restructuring in response to a challenging operating environment and financial discipline needs.

• Strategic shift prioritized outpatient oncology services, divestment of non-core and hospital assets, and operational turnaround.

• Significant cash flow pressures from major payor defaults (Unimed FERJ: R$864.9M) and Banco Master deposit losses (R$431M).

• R$1.4B capital increase in 4Q25 via debt-to-equity swap and subscription warrants to reduce net debt and restore operational discipline.

• Ongoing creditor negotiations and operational focus to address liquidity and deleveraging.

Financial highlights

• Gross revenue for 2025 was R$6.3B, down 7% year-over-year; net revenue was R$5.7B, down 7.8%.

• Adjusted EBITDA for 2025 was R$831.0M (margin 14.5%), down over 30% year-over-year; 4Q25 Adjusted EBITDA was R$238.8M (margin 17.4%).

• Net loss for 2025 was R$3,671.1M; adjusted net loss (ex-LTIP and impairment) was R$945.0M.

• Average ticket per procedure increased to BRL 10,100, but total procedures declined.

• Gross margin for the year was 32%, with quarterly cash gross margin reaching 36.8%.

Outlook and guidance

• Management focuses on operational recovery, profitability restoration, and strategic adjustments, including possible inorganic initiatives.

• Debt amortization schedule and restructuring under negotiation to align with cash flow generation.